human anti-IL-6 mAb (Wuxi Yaominglikang Biopharmaceutical)

N/A

Report date: 2025/03/20 15:23:20

Base Information

Drug Namehuman anti-IL-6 mAb (Wuxi Yaominglikang Biopharmaceutical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIL-6 receptor antagonists
TargetsIL-6 receptor
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesWuxi Medimmune Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuxi Medimmune Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A